Cargando…

SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report

Gastric cancer (GC) is the fourth most common cancer worldwide, with overall 5-year survival rate of approximate 20%. Although multimodal treatments that combine surgery with chemotherapy and immunotherapy have been shown to improve survival, pathological complete response (pCR) is rare in advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dezhao, Liu, Mei, Wang, Jinhuan, Guo, Jia, Xu, Ningzhi, Lu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792132/
https://www.ncbi.nlm.nih.gov/pubmed/36578494
http://dx.doi.org/10.3389/fimmu.2022.1073094
_version_ 1784859568013049856
author Li, Dezhao
Liu, Mei
Wang, Jinhuan
Guo, Jia
Xu, Ningzhi
Lu, Jun
author_facet Li, Dezhao
Liu, Mei
Wang, Jinhuan
Guo, Jia
Xu, Ningzhi
Lu, Jun
author_sort Li, Dezhao
collection PubMed
description Gastric cancer (GC) is the fourth most common cancer worldwide, with overall 5-year survival rate of approximate 20%. Although multimodal treatments that combine surgery with chemotherapy and immunotherapy have been shown to improve survival, pathological complete response (pCR) is rare in advanced GC patients with liver metastases. Pre-clinical studies and clinical trials have demonstrated the antitumor efficacy of invariant natural killer T (iNKT) cells in various malignancies, including GC. While multimodal therapy comprised of chemotherapy, anti-programmed cell death-1 (PD-1) therapy, and iNKT cell immunotherapy have not been reported in GC patients. This case report describes the treatment of an early 60s patient diagnosed with advanced stage IVB (T1N1M1) adenocarcinomas of gastric cardia with liver metastases who received multimodal therapy comprised of SOX chemotherapy, anti-programmed cell death-1 (PD-1) therapy, and iNKT cell immunotherapy followed by surgical resection. Dramatic decreases in tumor area were observed in both the primary tumor and metastatic lesions following six cycles of SOX chemotherapy and iNKT cell immunotherapy, and four cycles of anti-PD-1 therapy. This combined treatment resulted in the transformation of a remarkably large, unresectable liver metastases into a resectable tumor, and the patient received total gastrectomy with D2 lymph node dissection and liver metastasectomy. Subsequent pathological examination detected no cancer cells in either the primary site or liver metastatic lesions, supporting the likelihood that this treatment achieved pCR. To our knowledge, this report represents the first case of a metastatic gastric cancer patient displaying pCR after six months of multimodal therapy, thus supporting that a SOX chemotherapy, anti-PD-1 therapy, and iNKT cell immunotherapy combination strategy may be effective for treating, and potentially curing, patients with advanced gastric adenocarcinoma.
format Online
Article
Text
id pubmed-9792132
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97921322022-12-27 SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report Li, Dezhao Liu, Mei Wang, Jinhuan Guo, Jia Xu, Ningzhi Lu, Jun Front Immunol Immunology Gastric cancer (GC) is the fourth most common cancer worldwide, with overall 5-year survival rate of approximate 20%. Although multimodal treatments that combine surgery with chemotherapy and immunotherapy have been shown to improve survival, pathological complete response (pCR) is rare in advanced GC patients with liver metastases. Pre-clinical studies and clinical trials have demonstrated the antitumor efficacy of invariant natural killer T (iNKT) cells in various malignancies, including GC. While multimodal therapy comprised of chemotherapy, anti-programmed cell death-1 (PD-1) therapy, and iNKT cell immunotherapy have not been reported in GC patients. This case report describes the treatment of an early 60s patient diagnosed with advanced stage IVB (T1N1M1) adenocarcinomas of gastric cardia with liver metastases who received multimodal therapy comprised of SOX chemotherapy, anti-programmed cell death-1 (PD-1) therapy, and iNKT cell immunotherapy followed by surgical resection. Dramatic decreases in tumor area were observed in both the primary tumor and metastatic lesions following six cycles of SOX chemotherapy and iNKT cell immunotherapy, and four cycles of anti-PD-1 therapy. This combined treatment resulted in the transformation of a remarkably large, unresectable liver metastases into a resectable tumor, and the patient received total gastrectomy with D2 lymph node dissection and liver metastasectomy. Subsequent pathological examination detected no cancer cells in either the primary site or liver metastatic lesions, supporting the likelihood that this treatment achieved pCR. To our knowledge, this report represents the first case of a metastatic gastric cancer patient displaying pCR after six months of multimodal therapy, thus supporting that a SOX chemotherapy, anti-PD-1 therapy, and iNKT cell immunotherapy combination strategy may be effective for treating, and potentially curing, patients with advanced gastric adenocarcinoma. Frontiers Media S.A. 2022-12-12 /pmc/articles/PMC9792132/ /pubmed/36578494 http://dx.doi.org/10.3389/fimmu.2022.1073094 Text en Copyright © 2022 Li, Liu, Wang, Guo, Xu and Lu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Dezhao
Liu, Mei
Wang, Jinhuan
Guo, Jia
Xu, Ningzhi
Lu, Jun
SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
title SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
title_full SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
title_fullStr SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
title_full_unstemmed SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
title_short SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report
title_sort sox chemotherapy with anti-pd-1 and inkt cell immunotherapies for stage iv gastric adenocarcinoma with liver metastases: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792132/
https://www.ncbi.nlm.nih.gov/pubmed/36578494
http://dx.doi.org/10.3389/fimmu.2022.1073094
work_keys_str_mv AT lidezhao soxchemotherapywithantipd1andinktcellimmunotherapiesforstageivgastricadenocarcinomawithlivermetastasesacasereport
AT liumei soxchemotherapywithantipd1andinktcellimmunotherapiesforstageivgastricadenocarcinomawithlivermetastasesacasereport
AT wangjinhuan soxchemotherapywithantipd1andinktcellimmunotherapiesforstageivgastricadenocarcinomawithlivermetastasesacasereport
AT guojia soxchemotherapywithantipd1andinktcellimmunotherapiesforstageivgastricadenocarcinomawithlivermetastasesacasereport
AT xuningzhi soxchemotherapywithantipd1andinktcellimmunotherapiesforstageivgastricadenocarcinomawithlivermetastasesacasereport
AT lujun soxchemotherapywithantipd1andinktcellimmunotherapiesforstageivgastricadenocarcinomawithlivermetastasesacasereport